These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 34314037)
1. The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination. Kaneko S; Kurosaki M; Sugiyama T; Takahashi Y; Yamaguchi Y; Nagasawa M; Izumi N J Med Virol; 2021 Dec; 93(12):6813-6817. PubMed ID: 34314037 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765 [TBL] [Abstract][Full Text] [Related]
3. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay. Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668 [TBL] [Abstract][Full Text] [Related]
7. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
8. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination. Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402 [TBL] [Abstract][Full Text] [Related]
9. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
10. Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel. Romero-Ibarguengoitia ME; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; González-Cantú A; Barco-Flores IA; González-Facio R; Montelongo-Cruz LP; Del Rio-Parra GF; Garza-Herrera MR; Leal-Meléndez JA; Sanz-Sánchez MÁ PLoS One; 2022; 17(3):e0263942. PubMed ID: 35235587 [TBL] [Abstract][Full Text] [Related]
11. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205 [TBL] [Abstract][Full Text] [Related]
12. BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients. Yau K; Tam P; Chan CT; Hu Q; Qi F; Abe KT; Kurtesi A; Jiang Y; Estrada-Codecido J; Brown T; Liu L; Siwakoti A; Leis JA; Levin A; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA Clin J Am Soc Nephrol; 2024 Jan; 19(1):85-97. PubMed ID: 37847518 [TBL] [Abstract][Full Text] [Related]
13. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
14. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status. Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577 [TBL] [Abstract][Full Text] [Related]
15. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
16. Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation. Struck F; Schreiner P; Staschik E; Wochinz-Richter K; Schulz S; Soutschek E; Motz M; Bauer G J Med Virol; 2021 Dec; 93(12):6765-6777. PubMed ID: 34387884 [TBL] [Abstract][Full Text] [Related]
17. Investigation of Anti-SARS-CoV-2-specific IgG Levels in Breast Milk after Vaccination or COVID-19 Infection. Temocin F; Çaycı YT; Seren C; Kuruoglu T; Atilla A; Birinci A; Tanyel E Am J Perinatol; 2024 May; 41(S 01):e3085-e3090. PubMed ID: 37846474 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans. Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM Front Immunol; 2021; 12():728021. PubMed ID: 34646267 [TBL] [Abstract][Full Text] [Related]
19. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972 [TBL] [Abstract][Full Text] [Related]
20. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents. Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Picot MC J Am Med Dir Assoc; 2022 May; 23(5):750-753. PubMed ID: 35311651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]